Safety Study of NNZ-2566 in Healthy Female Subjects

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to obtain evidence of the safety of NNZ-2566 in healthy female volunteers and to determine the pharmacokinetics (PK) of NNZ-2566 in healthy female volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neuren Pharmaceuticals Limited

Criteria

Inclusion Criteria:

• Aged between 18 years and 50 years (inclusive).

• Females only.

• Weight 50 to 105 kg

• BMI of 18 to 30 kg/m2.

• General Health: Healthy, determined by a medical history with particular attention to:

• a drug history identifying any known drug allergies and the presence of drug abuse;

• any chronic use of medication; and

• a thorough review of body systems. This will also be determined by having no clinically significant abnormal findings on physical examination, which includes an electrocardiogram (ECG), which in the opinion of the Investigator would jeopardize the safety of the subject or impact on the validity of the study results.

• Venous Access: Volunteers with adequate venous access in their left and right arm to allow collection of blood samples and drug administration.

• Language: Fluent in the English language.

• Informed Consent: Have voluntarily given written informed consent to participate in this study.

Exclusion Criteria:

• Pregnant and lactating females are excluded from participating in the study.

• History of allergy and/or hypersensitivity to any of the stated ingredients of the formulations.

• History of clinically significant gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or hematological disorders.

• Any history of asthma during the last 10 years.

• A creatinine clearance of less than 75 mL/min.

• Any predisposing condition that might interfere with the absorption, distribution, metabolism, and/or excretion of the investigational product.

• History of abnormal bleeding tendencies or thrombophlebitis unrelated to venepuncture or intravenous cannulation.

• History of Hepatitis B, a positive test for Hepatitis B surface antigen, a history of Hepatitis C, a positive test for Hepatitis C antibody, a history of HIV infection or demonstration of HIV antibodies.

• Pregnancy.

• Any evidence of organ dysfunction, or any clinically significant clinical laboratory value, including a liver function test (LFT) > 1.5 x upper limit of normal (ULN).

• Difficulty abstaining from alcohol during the 48 hours prior to dose administration and until completion of blood sampling at exit assessment.

• History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit, or positive urine drug screen for drugs of abuse.

• Difficulty in abstaining from any prescription medications for 14 days prior to dose administration and for the duration of the study.

• Difficulty in abstaining from over-the-counter (OTC) medications or herbal supplements for 14 days prior to dose administration and for the duration of the study, (with the exception of occasional analgesia, vitamin and other nutrient supplement use, at the discretion of the Investigator).

• Difficulty in abstaining from food and/or beverages that contain caffeine or other xanthines, (e.g., coffee, tea, cola and chocolate) during the 24 hours prior to dose administration and whilst confined at the clinical study facility.

• History of any psychiatric illness which may impair the ability to provide written informed consent.

• Poor protocol compliers or those unlikely to attend.

• Receipt of any drug as part of a research study within 30 days of initial dose administration in this study.

• Standard blood donation (usually 550 mL) within the 12-week period before dose administration.

• Unusual dietary habits and excessive or unusual vitamin intakes.

• Vaccination or immunizations within 30 days of initial dose administration.

• QT/QTc Exclusions i.e., a marked baseline prolongation of corrected QT interval > 450 ms in two ECGs, or a history of risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).